Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace
Notice Number:
NOT-MH-24-115

Key Dates

Release Date:

January 8, 2024

First Available Due Date:
April 05, 2024
Expiration Date:
April 06, 2027

Related Announcements

  • March 3, 2021 - Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace. See Notice NOT-MH-21-125 (Reissue)
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). See Notice PA-23-230
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed). See Notice PA-23-232

Issued by

National Institute of Mental Health (NIMH)

National Eye Institute (NEI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Drug Abuse (NIDA)

National Institute of Neurological Disorders and Stroke (NINDS)

National Center for Complementary and Integrative Health (NCCIH)

Purpose

This Notice of Special Interest (NOSI) encourages the translation of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative-supported technologies from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications that propose to further develop, optimize, validate and scale such technologies for commercial dissemination. Additionally, SBIR and STTR applications supporting the development and commercialization of novel technologies that fit within the mission of the BRAIN Initiative are encouraged.

Background 

The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. It is expected that the application of these new tools and technologies will ultimately lead to new ways to identify, treat, cure, and even prevent brain disorders. 

NIH is one of several federal agencies involved in the BRAIN Initiative. Planning for the NIH component of the BRAIN Initiative is guided by the long-term scientific plan, "BRAIN 2025: A Scientific Vision," which details seven high-priority research areas and calls for a sustained federal commitment of $4.5 billion over 12 years. This NOSI is based on the NIH's careful consideration of the recommendations of the BRAIN 2025 Report and input from the NIH BRAIN Multi-Council Working Group and the Advisory Committee to the NIH Director BRAIN Initiative Working Group 2.0

NIH encourages BRAIN Initiative applications from investigators who are underrepresented in the biomedical, behavioral, or clinical research workforce (see NSF data and the most recent report on Women, Minorities, and Persons with Disabilities in Science and Engineering). Such individuals include those from underrepresented racial and ethnic groups as well as individuals with disabilities. 

NIH also encourages businesses to participate in the BRAIN Initiative. It is possible for companies to submit applications directly to BRAIN Initiative Notices of Funding Opportunities (NOFOs) or to collaborate with academic researchers in joint submissions.  In addition, the NIH continues to have a substantial annual investment in neuroscience research and in technology development through the SBIR and STTR programs. Small businesses developing technologies relevant to this NOSI should consider applying to the SBIR/STTR programs for BRAIN Initiative funding by linking their application to this Notice number NOT-MH-24-115.  Potential applicants are strongly encouraged to contact Scientific/Program staff if they have any questions about the best NOFO for their research. 

This is a reissue of NOT-MH-21-125, with modified scientific priorities.

Objectives 

The BRAIN Initiative and other research sponsors have invested a significant amount of funds in the development of new technologies to study and understand the brain, from basic and clinical perspectives, through a variety of mechanisms. This investment has produced a large number of innovative neuroscience technologies. While these innovations are put to good use by their developers, non-commercial developers often lack the resources and product development training to make their technologies robust and easy to use by the broad neuroscience community. Moreover, ongoing support to maintain and update technologies in non-commercial settings is difficult to obtain. Consequently, the promise of these advanced technologies is often realized only by industry. The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures report highlights the need to further support the dissemination of innovative neuroscience technologies. 

This NOSI is intended to alert Small Business Concerns (SBCs) and partnering institutions that there is a need to help move useful BRAIN Initiative-developed technologies and BRAIN Initiative-relevant technologies from non-commercial laboratories into the commercial marketplace. These translational projects can be submitted through the SBIR and STTR Programs. 

Supported research and development will include further development, optimization, validation and scaling of technologies for commercial dissemination and will likely require close collaboration between the original developers of these technologies and SBCs. These partnerships may be accomplished in a number of ways, including the use of multiple program directors/principal investigators. 

BRAIN Priority Areas were identified in the BRAIN 2025 Report; applications from SBCs that aim to commercialize technologies relating to these priority areas are encouraged: 

1. Cell Type: identify and provide experimental access to the different brain cell types to determine their roles in health and disease. 

2. Circuit Diagrams: generate circuit diagrams that vary in resolution from synapses to the whole brain. 

3. Monitor Neural Activity: produce a dynamic picture of the functioning brain by developing and applying improved methods for large-scale monitoring of neural activity. 

4. Interventional Tools: link brain activity to behavior with precise interventional tools that change neural circuit dynamics. 

5. Theory & Data Analysis Tools: produce conceptual foundations for understanding the biological basis of mental processes through the development of new theoretical and data analysis tools. 

6. Human Neuroscience: develop innovative technologies to understand the human brain; create and support integrated human brain research networks. 

7. Integrated Approaches: integrate new technological and conceptual approaches produced in Goals #1-6 to discover how dynamic patterns of neural activity are transformed into cognition, emotion, perception, and action in health and disease. 

Responsive Areas of Research 

Examples of technologies responsive to this NOSI are listed below. This list is non-exhaustive and meant to provide a representation of appropriate applications from SBCs that support or enable the goals of the BRAIN Initiative. 

  • Improved Microscopy Imaging-ability to enhance single cell resolution while maintaining spatial and depth resolution, in vivo and ex vivo, automation of processes 
  • Improved Measures of Brain Activity - multielectrode, range of depths, correlation with imaging/behavior, ability to streamline analysis, record for long periods of time, collect during social interactions, decreasing size, improving signal-to-noise ratio (S/N), less injury 
  • Improved technologies for single cell transcriptomic/epigenomic analysis 
  • Generation of molecular tools to specifically access, manipulate and monitor brain cell types across species 
  • Novel technologies for measuring and quantifying human and non-human animal behavior 
  • Novel or improved preclinical and clinical imaging technologies with the potential to enhance our understanding of complex circuit function or neuropathology 
  • Clinical Electrophysiology - dry electrodes, easy application, clinical grade processing/analysis pipelines, combination image-related technology products, determination of minimal electrode ability to reflect brain activity vs. multi-electrodes and sufficiency for use in clinical studies/trials 
  • MRI (including fMRI) - technical approaches to standardization, improved temporal/spatial resolution (including pediatric resolution), correlation with EEG/other activity measures 
  • Software platforms and knowledge management systems for large datasets, such as molecular, imaging and electrophysiology to enable streamlined data processing and analysis 

Applicants are strongly encouraged to consult Program Staff regarding the appropriateness of the planned application to the BRAIN Initiative’s mission, scientific areas of interests and programmatic priorities. 

Awardees will be expected to participate in the NIH I-Corps Program or the Concept to Clinic: Commercializing Innovation (C3i) Program to help advance the commercial opportunity of the technology. 

Application and Submission Information

Applicants must select the IC and associated NOFO to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that NOFO. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those NOFO are acceptable and based on usual application-IC assignment practices.

This notice applies to due dates on or after April 5, 2024, and subsequent receipt dates through April 6, 2027.

Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice.

NOFO

Title

First Available Due Date

Expiration Date

Participating IC(s)

PA-23-230PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed).4/5/20244/6/2024NIMH, NEI, NIA, NIAAA, NIBIB, NINDS, NIDA, NIDCD, NICHD, NCCIH
PA-23-232PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)4/5/20244/6/2024NIMH, NEI, NIA, NIAAA, NIBIB, NINDS, NIDA, NIDCD, NICHD, NCCIH

All instructions in the SF424 (R&R) Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-MH-24-115” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.

Scientific/Research Contact(s)

Margaret C. Grabb, Ph.D. 
National Institute of Mental Health (NIMH) 
Phone: 301-443-3563 
Email: mgrabb@mail.nih.gov 

Paek Lee, Ph.D. 
National Eye Institute (NEI) 
Phone: 301-435-8164 
E-mail: paek.lee@nih.gov

Yuan Luo, Ph.D. 
National Institute on Aging (NIA) 
Phone: 301-496-9350 
Email: yuan.luo@nih.gov

Megan Ryan, M.B.A. 
National Institute On Alcohol Abuse And Alcoholism (NIAAA) 
Phone: 301-443-4225 
E-mail: mryan1@mail.nih.gov

Kari Ashmont, Ph.D. 
National Institute Of Biomedical Imaging And Bioengineering (NIBIB) 
Phone: 301-451-4772 
E-mail: kari.ashmont@nih.gov

Toyin Ajisafe, Ph.D. 
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 
Phone: 301-827-9242 
E-mail: toyin.ajisafe@nih.gov

Roger Miller, Ph.D. 
National Institute on Deafness and Other Communication Disorders (NIDCD) 
Phone: 301-402 3458 
E-mail: millerr@nidcd.nih.gov

Leonardo Maria Angelone, Ph.D. 
National Institute on Drug Abuse (NIDA) 
Phone: 301-827-5946 
E-mail: Leonardo.angelone@nih.gov

Taryn Aubrecht, Ph.D. 
National Institute of Neurological Disorders and Stroke (NINDS) 
Phone: 301-496-1779 
E-mail: taryn.aubrecht@nih.gov

Emrin Horgusluoglu, Ph.D.
National Center for Complementary and Integrative Health (NCCIH) 
Phone: 240-383-5302 
Email: emrin.horgusluoglu-moloch@nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Maggie Paolini 
National Institute of Mental Health (NIMH) 
Phone: 301-443-2746 
Email: maggie.paolini@nih.gov

Karen Robinson Smith 
National Eye Institute (NEI) 
Phone: 301-435-8178 
E-mail: Karen.Robinson.Smith@nei.nih.gov

Jessi Perez  
National Institute on Aging (NIA) 
Phone: 301-403-7739 
Email: jessi.perez@nih.gov

Jeffrey Thurston 
National Institute On Alcohol Abuse And Alcoholism (NIAAA) 
Phone: 301-443-9801 
E-mail: Jeffrey.thurston@nih.gov

James Huff 
National Institute of Biomedical Imaging and Bioengineering (NIBIB) 
Telephone: 301-451-4786 
Email: james.huff@nih.gov

Mindy Bixby 
Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD) 
Phone: 301-402-3204 
E-mail: mindy.bixby@nih.gov

Christopher Myers 
National Institute on Deafness and Other Communication Disorders (NIDCD) 
Phone: 301-435-0713 
E-mail: myersc@nidcd.nih.gov

Amy Connolly 
National Institute On Drug Abuse (NIDA) 
Phone: 301-827-4457 
E-mail: amy.connolly@nih.gov

Chief Grants Management Officer 
National Institute of Neurological Disorders and Stroke (NINDS) 
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Debbie Chen 
National Center for Complementary and Integrative Health (NCCIH) 
Phone: 301-594-3788 
Email: debbie.chen@nih.gov